173 related articles for article (PubMed ID: 31769393)
1. Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India.
Kuttiatt VS; Somani RK; Swaminathan S; Krishnamoorthy K; Weil GJ; Purushothaman J
Am J Trop Med Hyg; 2020 Jan; 102(1):96-99. PubMed ID: 31769393
[TBL] [Abstract][Full Text] [Related]
2. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
[TBL] [Abstract][Full Text] [Related]
5. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
Fischer PU; King CL; Jacobson JA; Weil GJ
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005163. PubMed ID: 28056015
[No Abstract] [Full Text] [Related]
6. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018.
Willis GA; Mayfield HJ; Kearns T; Naseri T; Thomsen R; Gass K; Sheridan S; Graves PM; Lau CL
PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008854. PubMed ID: 33253148
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
Edi C; Bjerum CM; Ouattara AF; Chhonker YS; Penali LK; Méité A; Koudou BG; Weil GJ; King CL; Murry DJ
PLoS Negl Trop Dis; 2019 May; 13(5):e0007325. PubMed ID: 31107869
[TBL] [Abstract][Full Text] [Related]
8. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
[TBL] [Abstract][Full Text] [Related]
10. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
[TBL] [Abstract][Full Text] [Related]
11. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.
Budge PJ; Herbert C; Andersen BJ; Weil GJ
PLoS Negl Trop Dis; 2018 May; 12(5):e0006454. PubMed ID: 29768412
[TBL] [Abstract][Full Text] [Related]
12. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008106. PubMed ID: 32176703
[TBL] [Abstract][Full Text] [Related]
13. Role of community empowerment in the elimination of lymphatic filariasis in south India.
Rajendran R; Sunish IP; Munirathinam A; Ashok Kumar V; Tyagi BK
Trop Biomed; 2010 Apr; 27(1):68-78. PubMed ID: 20562816
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings.
James A; Coffeng LE; Blok DJ; King JD; de Vlas SJ; Stolk WA
Clin Infect Dis; 2024 Apr; 78(Supplement_2):S131-S137. PubMed ID: 38662696
[TBL] [Abstract][Full Text] [Related]
15. Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study.
Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
Drug Saf; 2023 Oct; 46(10):961-974. PubMed ID: 37552438
[TBL] [Abstract][Full Text] [Related]
16. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study.
Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
Infect Dis Poverty; 2024 Jun; 13(1):44. PubMed ID: 38867265
[TBL] [Abstract][Full Text] [Related]
18. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
[TBL] [Abstract][Full Text] [Related]
19. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
King CL; Suamani J; Sanuku N; Cheng YC; Satofan S; Mancuso B; Goss CW; Robinson LJ; Siba PM; Weil GJ; Kazura JW
N Engl J Med; 2018 Nov; 379(19):1801-1810. PubMed ID: 30403937
[TBL] [Abstract][Full Text] [Related]
20. A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
Coulibaly YI; Dicko I; Keita M; Keita MM; Doumbia M; Daou A; Haidara FC; Sankare MH; Horton J; Whately-Smith C; Sow SO
PLoS Negl Trop Dis; 2013; 7(5):e2221. PubMed ID: 23675549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
